Alfred E Mann Foundation For Scientific Research is a 501(c)(3) organization based in Valencia, California, registered in 1986, with $18,144,382 in FY2024 revenue. CharityIndex grades it C, and it directs about 88% of spending to programs.
Revenue (FY2024)
$18.1M
▼ 58.9% vs prior year
Science & Tech median: $288K
Expenses (FY2024)
$41.8M
Net assets
$347.0M
Employees
137
Rated on 4 of 4 criteria.
Held down by its weakest criterion — a strong score on one criterion can't hide a weak one.
How the rating works →Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Alfred E Mann Foundation For Scientific Research: 88% to programs earns a A on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Alfred E Mann Foundation For Scientific Research: 100 mo reserves · -130% margin earns a F on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Alfred E Mann Foundation For Scientific Research: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Alfred E Mann Foundation For Scientific Research: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Conduct medical and scientific research
New project developmentthis program covers (a) the monitoring and evaluation of several early stage advanced research and development efforts underway that are directed at developing - innovative technologies, project ideas and concepts before they progress to the status of full-fledged development programs, and (b) ongoing efforts related to the advancement of commercial development and protection of intellectual property of these projects across the development lifecycle. the team comprises the full range of expertise available at amf, including - executive management, research scientists and engineers, legal and intellectual property experts, business development strategists and analysts.expenses may include ongoing participation in the development effort including research and development support, collaboration management, conference and professional society meeting attendance, service in management or on the board of directors of spinout entities, patent prosecution and the prosecution of infringement actions to protect the value of the intellectual property we create. in addition to payroll expenses and direct expenses paid to outside vendors for goods and services related to projects, expenses in this program may include travel expenses, patent prosecution expenses and fees, legal fees (for internal and outside legal counsel) for expenses to create, preserve and protect intellectual property from infringement and remedy past infringement, and incentive and other compensation payments to employees and others related to these programs and actions. in some cases, certain of these expenditures might be incurred long after the projects have been launched into spinout companies or licensed to third parties.revenues associated with these projects (some of which may accrue long after the project and any related program have been out-licensed or launched into a spinout company) may include recoveries of judgments or settlements from patent infringement matters, royalties on net sales of licensed products, milestone payments, ongoing contract r&d from partners, licensees and spinout companies, interest, and proceeds of liquidity events (e.g., initial public offerings, acquisitions) involving retained equity interests in projects that have been spun out as startup companies.status:design and development activities are underway for a new bioelectronic program based on the business case analysis conducted in the prior year. these activities included generation of initial system requirements, assembly of a team of key opinion leaders with domain expertise, and the initiation of some fundamental applied research in the area of novel electrode design, including completion of pre-clinical testing. additionally, the business development team, along with executive management and other staff, performed preliminary due diligence on a number of assets.
Implantable neuromodulation project #1 to treat chronic disease the aim of the amf program is to develop a neurostimulation system that will improve medical outcomes at a lower cost and/or higher patient satisfaction than currently available treatment options. such a system will consist of a fully implantable neural stimulator for seamless operation and requiring minimal interaction from a patient, with the goal of offering a higher level of patient satisfaction, adoption, and compliance.status:final design verification testing activities of the implantable device and externals are underway in support of a first-in-human study. design and manufacturing improvements have been made; pre-clinical animal studies were completed.
Implantable neuromodulation project #2: - to treat a range of neurological conditions. the system will consist of an implantable neural stimulator and externals designed to maximize therapy outcomes and patient satisfaction while minimizing system costs.status:planning, design, and development of the first in-human implant and externals is underway; feasibility planning a
Revenue declined from $19.6M (FY2013) to $18.1M (FY2024) across 11 reported years.
Financial snapshot
Operating margin
-130.2%
Spent more than it raised in the latest fiscal year.
Total assets
$353.4M
Total liabilities
$6.4M
Net assets
$347.0M
Salaries & benefits
$21.2M
51% of expenses
Board members
5
4 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $18,144,382▼58.9% | $41,776,524▲31.2% | $346,976,761▼5.2% | $353,361,768▼5.1% | 990 |
| 2023 | $44,147,259▲42.2% | $31,844,936▲39.5% | $365,867,901▲8.0% | $372,537,856▲8.1% | 990 |
| 2022 | $31,054,042▼75.8% | $22,822,234▲25.8% | $338,683,494▼8.9% | $344,680,217▼7.9% | 990 |
| 2021 | $128,538,828▼43.1% | $18,142,697▼19.1% | $371,696,184▲22.0% | $374,343,975▲21.8% | 990 |
| 2020 | $225,963,433▲9672% | $22,418,205▲61.8% | $304,680,013▲540% | $307,411,437▲420% | 990 |
| 2019 | $2,312,474▲436% | $13,859,108▲5.9% | $47,580,238▼3.6% | $59,071,014▲18.1% | 990 |
| 2017 | $431,624▼56.3% | $13,081,377▼14.8% | $49,364,115▼20.2% | $50,020,916▼21.3% | 990 |
| 2016 | $986,677▼78.3% | $15,345,907▼11.1% | $61,870,551▼16.3% | $63,522,432▼22.6% | 990 |
| 2015 | $4,540,535▼40.2% | $17,253,210▼3.6% | $73,956,439▼20.8% | $82,113,434▼24.4% | 990 |
| 2014 | $7,594,704▼61.3% | $17,902,645▼26.0% | $93,414,206▼9.8% | $108,633,540▼5.3% | 990 |
| 2013 | $19,639,842 | $24,203,179▲8.4% | $103,542,213▼2.7% | $114,740,000▼5.8% | 990 |
| 2012 | — | $22,317,539▼9.6% | $106,453,838▼5.1% | $121,867,281▼4.2% | 990 |
| 2011 | — | $24,699,740▲12.3% | $112,213,215▼16.1% | $127,153,690▼14.7% | 990 |
| 2010 | — | $21,995,370 | $133,670,177 | $149,147,272 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Robert Greenberg — $1,176,449 (2.82% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Robert Greenberg | Ceo/president/chair of the Board | 44 | $1,176,449 |
| Farah Boroomand | Chief Financial Officer/treasurer | 44 | $510,007 |
| Corey Dishmon | Chief Business and Legal Officer | 40 | $404,186 |
| John Rivera | Vice President, Product Development | 41 | $357,505 |
| Neil Talbot | Vp, Research and Technology | 42 | $321,393 |
| Shawn Lewis | Vice President, Human Resources | 40 | $318,397 |
| Brian Mech | Vp, Strategy | 40 | $306,807 |
| Cedric Navarro | V.p. Quality Assurance, Reg. Affairs, Interim | 40 | $283,665 |
| Carl Buice | Senior Director, Project Management | 40 | $280,991 |
| Valma Klein | Vp, Clinical Affairs | 41 | $274,441 |
| Philip Lee | Secretary/assistant General Counsel | 40 | $216,632 |
| David Gill | Board Member | 1.5 | — |
| Heather Page | Board Member | 1.25 | — |
| Ken Weatherwax | Board Member | 1.25 | — |
| Richard Waugh | Board Member | 1.5 | — |
| Contractor | Services | Paid |
|---|---|---|
| Morgan Lewis & Bockius LLP | Legal Services | $3,758,302 |
| Stuart Karten Design (DBA Karten Design | R&d Consultants | $595,720 |
| Medix Staffing Solutions Inc | Software Consultants | $396,451 |
| Lewis Roca Rothgerber Christie LLP | Legal Services (patents) | $320,656 |
| Ubs Investment Management | Investment Management Fees | $309,937 |
1 grant to Alfred E Mann Foundation For Scientific Research totaling $25K, reported by foundations on their Schedule I filings.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| Donor Advised Charitable Giving | Education | 2014 | $25,000 |
Explore more
Data for Alfred E Mann Foundation For Scientific Research (EIN 95-4002032) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.